Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Diseases of the Esophagus

Low-Dose Involved-Field Rt, Plus Immunochemotherapy Showed Excellent Efficacy and Low Toxicities in Unresectable La-Escc: A Prospective Phase Ii Study

View Full Paper
Ask AI
Bookmark
Share

Authors

YCYueyun Chen

Discussion

Loading...

Member takes

Overview

A prospective phase II trial demonstrated a 75% 1-year progression-free survival in unresectable LA-ESCC, indicating promising efficacy and manageable toxicities.

Key Points

  • The trial reported a 1-year progression-free survival rate of 75% and an overall response rate of 96.2%.
  • Among the 26 evaluable patients, all experienced treatment-related adverse events, with 63.2% having Grade 3 or 4 toxicities.
  • The combination of low-dose involved-field RT, camrelizumab, and chemotherapy allowed for manageable side effects, including primarily esophagitis.
  • Ongoing patient follow-up aims to further validate these encouraging findings in unresectable LA-ESCC.

Cite This Study

Yueyun Chen (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b8f8https://doi.org/10.1093/dote/doaf061.030
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1107. CAMRELIZUMAB AND LOW-DOSE RADIOTHERAPY WITH CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (NICE-RT STUDY): PRELIMINARY RESULTS2025
  2. 2236. SAFETY AND EFFICACY OF CAMRELIZUMAB COMBINED WITH RADIOTHERAPY AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025
  3. 3192. INDUCTION IMMUNOCHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY FOR UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (RICE): PRELIMINARY RESULTS2025
  4. 4Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma2025
  5. 5150. NEOADJUVANT CHEMOIMMUNOTHERAPY WITH ADAPTIVE RADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: STUDY PROTOCOL FOR A PROSPECTIVE MULTICENTER PHASE II TRIAL2025